Journal Article

STAT3 regulated ARF expression suppresses prostate cancer metastasis

Culig, Zoran, Gruber, Wolfgang, Merkel, Olaf, Unger, Christine, Scharpf, Marcus, Poli, Valeria, Eferl, Robert, Dolznig, Helmut, Skucha, Anna, Egger, Gerda, Susani, Martin, Javaheri, Tahereh, Marié, Isabelle J., Prutsch, Nicole, Schlederer, Michaela, Chalaris, Athena, Aberger, Fritz, Hassler, Melanie R., Mazal, Peter, Kennedy, Richard, Walker, Steven M., Turner, Suzanne D., Moriggl, Richard, Esterbauer, Harald, Aksoy, Osman, Braun, Martin, Perner, Sven, Haitel, Andrea, Levy, David E., Mikulits, Wolfgang, Malcolm, Tim, Pencik, Jan, Herac, Merima, Krämer, Oliver H., Fend, Falko, Moazzami, Ali, Blayney, Jaine K., Kenner, Lukas, Grebien, Florian, Rose-John, Stefan

2015

Overview

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten -deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19 ARF as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF–Mdm2–p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14 ARF expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition. IL6-STAT3 signaling is activated in prostate cancer, however inhibiting this pathway has not lead to a survival advantage in patients. Here, Pencik et al. show that loss of the IL6-STAT3 axis in mice and humans leads to metastasis due to loss of ARF, unravelling STAT3 and ARF as potential prognostic markers in prostate cancer.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Pub. Group
• Subject: 13 / 13/105 / 13/21 / 13/51 / 631/67/322 / 631/67/589/466 / 631/80/86 / 64 / 64/60 / 692/53/2422 / 82 / 96 / Animals / Biochemistry / Biology / Biomarkers / Cancer research / Cell and Molecular Biology / Cell Line / Cell- och molekylärbiologi / Cyclin-Dependent Kinase Inhibitor p16 - metabolism / Disease Progression / Genes, p16 / Health risks / Humanities and Social Sciences / Humans / Inactivation / Interleukin-6 - genetics / Interleukin-6 - metabolism / Laboratory animals / Male / Medical research / Metastasis / Mice / Mice, Transgenic / multidisciplinary / Mutation / Neoplasms, Experimental / Pathology / Phosphorylation / Prostate cancer / Prostatic Neoplasms - metabolism / Proto-Oncogene Proteins c-mdm2 - metabolism / PTEN Phosphohydrolase - genetics / Science / Science (multidisciplinary) / Senescence / STAT3 Transcription Factor - genetics / STAT3 Transcription Factor - metabolism / Tumor Suppressor Protein p53 - metabolism / Tumors / Veterinary medicine